Immune checkpoint inhibitors are a type of immunotherapy drug. Although traditional chemotherapeutic drugs are still the first-line treatment option for most cancer types, targeted immune therapies are becoming standard treatments for advanced-stage cancers. These drugs target cell surface checkpoint proteins to stimulate the immune system's recognition and destruction of cancer cells.
The global immune checkpoint inhibitors market is growing due to an increase in cancer prevalence across geographies and increased awareness of immune checkpoint inhibitors. Furthermore, technological advancements in cancer screening procedures, increased healthcare expenditures, an increase in government initiatives to alleviate cancer, and an increase in public awareness is expected to drive market growth. However, the high cost of research activities is expected to limit Immune checkpoint inhibitors' growth.
The global market for PD-L1 immune checkpoint inhibitors is relatively new, with products such as Bavencio, Tecentriq, and Imfinzi. The PD-1 drug class is responsible for the blockbuster products in the immune checkpoint inhibitors market (Keytruda and Opdivo). The rising cancer prevalence and increased FDA approvals are the primary factors expected to drive the immune checkpoint inhibitors market over the forecast period.
Read more @ https://bit.ly/3GZtarZ
